Despite initial high response rates to first-line treatment, the disease will ultimately recur in the majority of patients with advanced ovarian cancer (1). These patients will normally be offered second-line chemotherapy in order to obtain another response (2) or stabilization of the tumor burden (3). In a study by Eisenhauer et al of 704 platinum-pretreated ovarian cancer patients, histology, number of disease sites and size of the recurrent tumor were all found to be predictive factors for response to second-line chemotherapy (4). However, some patients with recurrent disease are refractory to second-line chemotherapy because of chemoresistant tumor clones (5), and these patients are exposed to the potential toxicity of the chemotherapy while the clinical benefit is dubious. The identification of pre-treatment factors predictive of chemoresistance will provide the clinician with a more rational tool to tailor second-line treatment to the individual patient. ABSTRACT: Objective: To examine if the determination of the levels of serological tumor markers at time of relapse had any predictive value for chemoresistance in the second-line treatment of ovarian cancer patients. Methods: From a registry of consecutive single-institution patients with epithelial ovarian carcinoma pretreated with paclitaxel plus platinum, we selected 82 patients with (a) solid tumor recurrence, and (b) second-line chemotherapy consisting of topotecan (platinum-resistant disease) or paclitaxel plus carboplatin (platinum-sensitive disease). Stored serum samples were analyzed for the biochemical tumor markers tetranectin, YKL-40, CASA (cancer-associated serum antigen), and CA 125. The serum tumor marker levels at time of relapse were correlated with response status at landmark time after 4 cycles of second-line chemotherapy. Univariate and multivariate logistic regression analyses (chemoresistant vs non-chemoresistant disease) were performed. Results: At landmark time, 26% of patients had progression according to the GCIG (Gynecologic Cancer Intergroup) progression criteria. In univariate logistic regression analysis, the tumor markers tetranectin (OR 0.4; 95% CI: 0.2-0.8; p=0.008), YKL-40 (OR 1.8; 95% CI: 1.0-3.3; p=0.045), and CASA (OR 1.8; 95% CI: 1.2-2.7; p=0.007) had predictive value for second-line chemoresistance, whereas serum CA 125 had no predictive value. In a multivariate logistic regression analysis, serum tetranectin and CASA both had independent predictive value for chemoresistance. The combined determination of tetranectin and CASA had a specificity of 90% with 33% sensitivity for the prediction of chemoresistance (area under the receiver operating characteristic curve = 0.78; 95% CI: 0.66-0.91; p=0.001). Conclusion: Low serum levels of tetranectin, or high serum levels of CASA or YKL-40, are associated with increased risk of second-line chemoresistance in patients with ovarian cancer. (Int J Biol Markers 2006; 21: 141-8)
INTRODUCTION
Measurement of biochemical tumor markers has a well-established role in the clinical management of patients with ovarian cancer (6, 7) . Given the potential of the müllerian epithelium to differentiate to various histological types of ovarian cancer, the simultaneous determination of several tumor markers may provide additional predictive information. CA 125 was selected because it is the gold standard tumor marker in epithelial ovarian cancer (8, 9) . CASA (cancer-associated serum antigen) was selected as a supplement for potential use in CA 125-negative patients (7) . Some ovarian cancer markers are not tumor-derived products but epiphenonema of metabolic changes caused by the presence of ovarian cancer cells. To reflect the patient host microenvironment, we selected the markers tetranectin and YKL-40. Tetranectin is an activator of plasminogen and might be a regulator of local proteolysis (10, 11) . Low serum levels of tetranectin have been associated with poor prognosis in patients with primary (12) and recurrent ovarian cancer (13) . YKL-40, secreted by cancer cells and macrophages, is a growth factor for connective tissue cells and probably has a function in the remodelling of the extracellular matrix and in angiogenesis (14, 15) . The term YKL-40 originates from the one-letter code of its 3 N-terminal amino acids and the molecular weight (40 kDa) . In clinical studies, a high serum YKL-40 level was found to be an adverse prognostic factor in patients with early stage (16) , advanced stage (17) , and recurrent ovarian cancer (18) and in other types of solid carcinomas (14) .
The aim of the study was to examine if the determination of the serum levels of the biochemical tumor markers CA 125, CASA, tetranectin, and YKL-40 at time of relapse had any predictive value for chemoresistance in the second-line treatment of ovarian cancer patients.
MATERIAL AND METHODS

Patients
The patients were selected from the CODOVA database (Copenhagen Database for Ovarian Carcinoma; The Danish Data Protection Agency No. 2000-41-0126), which has been previously described (19) . Briefly, since 1994, when paclitaxel-platinum was introduced as the standard first-line chemotherapy for epithelial ovarian carcinoma at the Rigshospitalet, all patients with ovarian tumors have been consecutively registered and the clinical parameters included in the CODOVA.
First-line chemotherapy consisted of paclitaxel (175 mg/m 2 as a 3-hour infusion) followed by either carboplatin (area under the curve [AUC] of 5) or cisplatin (75 mg/m 2 ) repeated every 3 weeks (20) . Second-line chemotherapy was standardized as follows: Patients with platinum-resistant disease (treatment-free interval ≤6 months after the end of first-line treatment) were offered single-drug treatment with topotecan (1.0 mg/m 2 , days 1-5 every 3 weeks) intravenously (21) . Patients with platinum-sensitive disease (treatment-free interval >6 months) were retreated with paclitaxel-carboplatin using a schedule similar to the first-line treatment (22) . Some patients with a treatment-free interval >6 months were treated with topotecan because of persistent neurotoxicity following first-line treatment.
Patient records were selected if they fulfilled the following criteria: 1) histopathologically verified epithelial ovarian carcinoma FIGO stage Ic-IV; 2) first-line chemotherapy with paclitaxel and a platinum compound; 3) solid tumor recurrence verified by imaging methods (CT or ultrasound scans); 4) second-line chemotherapy consisting of topotecan or paclitaxel-carboplatin; and 5) start of second-line chemotherapy after January 1 st , 1999.
Excluded were patients in whom no response evaluation following at least 4 cycles of second-line chemotherapy was performed for any reason including death.
Biochemical analyses
In all patients, blood samples were prospectively collected within 2 weeks before the start of second-line chemotherapy. Serum was separated by centrifugation at 2000 x g for 10 minutes and stored in aliquots at -80°C at the Statens Serum Institute (Copenhagen, Denmark) until analysis. All samples were processed into serum in less than 8 hours after venipuncture.
The biochemical tumor markers tetranectin, CASA, and CA 125 were all analyzed at the Statens Serum Institute (Copenhagen, Denmark), whereas YKL-40 was analyzed at Herlev Hospital (Copenhagen, Denmark). Tumor marker levels were measured in serum. All samples were tested in duplicate.
Tetranectin
An enzyme-linked immunosorbent assay (ELISA) based on the polyclonal rabbit antihuman tetranectin antibody A-371 (Dako, Glostrup, Denmark) was used for quantification of serum tetranectin (23) . The intra-assay and interassay coefficients of variation (CV) were 5.1% (n=123) and 8.8% (n=25), respectively, using a control sample of 10.9 mg/L.
YKL-40
YKL-40 levels were determined by a commercial YKL-40 ELISA kit (Quidel Corporation, Santa Clara, CA, USA). The YKL-40 assay is a sandwich enzyme immunoassay in a microtiter stripwell format. The Fab-fragment of a monoclonal anti-YKL-40 antibody conjugated to biotin binds to streptavidin on the strip and captures YKL-40 in standard, control, or sample. A polyclonal an-ti-YKL-40 antibody conjugated to alkaline phosphatase binds to the captured YKL-40. Bound enzyme activity is detected with p-nitrophenyl phosphate as substrate (24) . Analyses were performed according to the manufacturer's instructions. The intra-assay and interassay CVs were 4.3% (n=40) and 6.1% (n=100), respectively, using a control sample of 140 µg/L.
CASA
CASA analyses were determined by a commercial sandwich CASA-ELISA kit (Medical Innovations, Labrador, Queensland, Australia) (25) . Analyses were performed according to the manufacturer's instructions. The intra-assay and interassay CVs were 7.5% (n=8) and 11.9% (n=24), respectively, using a serum control with a CASA concentration of 15 U/mL.
CA 125
CA 125 levels were determined using a commercial CA 125 enzyme immunoassay (IMX, Abbott CA 125, Abbott Laboratories, Chicago, IL, USA) according to the manufacturer's instructions. The intra-assay and interassay CVs were 6.6% (n=60) and 6.2% (n=10), respectively, using a control sample of 30 U/mL.
Chemoresistance
Patients showing disease progression during secondline chemotherapy as their best response were considered to have second-line chemoresistance. The GCIG (Gynecologic Cancer Intergroup) definition of progression in ovarian cancer patients was applied (26) . Briefly, this definition is based on a combination of RECIST (Response Evaluation Criteria In Solid Tumors) (27) and validated CA 125 alterations. According to the guidelines, a patient may be declared to have progressive disease on the basis of either the objective RECIST criteria or the CA 125 criteria. The date of progression will be the date of the earlier of the 2 events if both are documented (26) .
Statistical methods
The study endpoint was progression at landmark time. The landmark was arbitrarily defined as the day of the first clinical evaluation following 4 cycles of secondline chemotherapy. The first response evaluation following cycle no. 4 was the one performed just prior to cycle no. 5, and it fell approximately 12 weeks after the start of second-line chemotherapy.
The predictive impact of the tumor marker levels at time of relapse was examined by univariate and multivariate logistic regression analysis. The probability of chemoresistance was modeled as chemoresistant versus non-chemoresistant disease. The discriminatory ability of the tumor markers was evaluated by ROC (Receiver Operating Characteristic) analyses. Values of tumor markers were entered as continuous variables. In order to assure linearity of the covariates in the regression models, serum concentrations of CASA, YKL-40, and CA 125 were log transformed (natural logarithm), whereas serum concentrations of tetranectin were fitted to the regression models without log transformation. The statistical assumptions underlying the models were checked by conventional statistical methods. Measures of association were calculated using the Spearman rank correlation coefficient.
The SAS statistical package, version 8.2 (SAS Inc. Cary, NC, USA) was used. P values less than 5% were considered significant.
RESULTS
Study population
A total of 101 patients met the inclusion criteria. Of these, 16 patients were excluded because of early death before landmark (n=13) or other reasons (n=3). In another 3 patients, the serum was no longer available for tumor marker measurement, leaving 82 patients for analysis.
The characteristics of these 82 patients are summarized in Table I . The patients received a median of 6 cycles (range 3-14 cycles) of paclitaxel-platinum as firstline treatment. The response rate was 80% (95% CI: 70-88%). The treatment-free interval, defined as the time in- terval between the end of first-line chemotherapy to the start of second-line chemotherapy, was median 3.5 months (range 0.5-34.9 months). Second-line chemotherapy was paclitaxel-carboplatin (n=47) or topotecan (n=35). A median of 6 cycles (range 4-16 cycles) of second-line chemotherapy was provided for salvage treatment. At landmark time following 4 cycles of second-line 
Tumor markers
The serum tumor marker levels at time of relapse in patients with subsequent chemoresistant or nonchemoresistant disease are depicted in Figure 1 . In univariate logistic regression analyses, serum tetranectin, YKL-40, and CASA were significantly predictive of chemoresistance at landmark time following 4 cycles of second-line chemotherapy (Tab. II, left). The predictive values of the 4 serological tumor markers are illustrated by ROC analyses (Fig. 2) .
In a multivariate logistic regression analysis including all 4 tumor markers, only serum tetranectin and CASA had independent predictive value for chemoresistance at landmark time (Tab. II, right). The predictive value of the combination of serum tetranectin and CASA (linear combination) is illustrated by ROC analyses (Fig. 3) . The specificity, defined as the ability to classify patients with non-chemoresistant disease correctly, was 90%. The sensitivity, defined as the ability to select patients with second-line chemoresistance, was 33%.
In another multivariate logistic regression analysis including the tumor markers tetranectin and CASA, and the clinical parameters treatment-free interval and performance status at start of second-line chemotherapy, the parameters serum tetranectin (OR 0.5; 95% CI: 0.2-1.0; p=0.04) and treatment-free interval (≤6 vs >6 months; OR 0.4; 95% CI: 0.2-0.6; p=0.0005) both had indepen-dent predictive value for chemoresistance at landmark time, whereas serum CASA (p=0.17) and performance status (0 vs 1-2; p=0.71) had non-significant predictability. Validation procedures confirmed the fits of the regression models.
Pairwise comparison of the tumor marker levels showed that they were not strongly correlated (-0.4 < r < 0.4). The correlation between serum tetranectin and treatment-free interval (r=0.27; p=0.01) and number of cycles of first-line chemotherapy (r=0.03; p=0.79), respectively, was weak.
DISCUSSION
Extensive studies have clarified multiple intracellular mechanisms related to chemoresistant tumor behavior, but fewer studies have focused on the importance of the microenvironmental host-tumor interaction (5, 28, 29) .
Our results indicate that the biochemical tumor markers tetranectin, YKL-40, and CASA are predictors of secondline chemoresistance in ovarian cancer patients. The pretreatment determination of the serum level of the markers might thus help to select patients who have a high risk of second-line chemoresistance. Furthermore, the findings highlight the importance of the extracellular matrix in tumor progression.
Tetranectin, a trimeric protein present in a variety of mesenchymal, epithelial, and endocrine cells, binds specifically to the kringle 4 domain of plasminogen, and it enhances the activation of plasminogen by tissue-type plasminogen activator (tPA) (10) . Tetranectin might be a regulator of local proteolysis, because activated plasminogen is believed to play a key role in the degradation of the extracellular matrix proteins, which is an important factor in the ability of the malignant tumor to infiltrate normal tissue (11, 30) . The predictive value of low serum levels of tetranectin might thus reflect alterations in the host microenvironment surrounding the tumor, which induce the tumor to display a chemoresistant behavior. This hypothesis is supported by the immunohistochemical findings of high extracellular tetranectin concentrations in the malignant tumors in combination with low serum tetranectin values (23) . Another potential mechanism might be that the cytotoxic agents on their passage from the intravasal location to the tumor cells are inactivated, or their passage is impeded, but this remains speculative.
Interestingly, the median level of tetranectin (15.9 mg/L) in this population of ovarian cancer patients was higher than in other patient series. In a study of 65 patients with primary ovarian cancer, Hogdall et al reported a median tetranectin value of 7.3 mg/L (12) . In a heterogeneous series of 70 pretreated ovarian cancer patients, Deng et al reported a median tetranectin level of 10.8 mg/L (13) . In comparison, a mean level of 11.6 mg/L in 458 healthy women was previously reported (31) . Because of the finding of unexpected high levels of tetranectin, we remeasured older serum samples and used the plasma standard previously published (31) . On reanalyzing 8 samples, we found no significant difference in tetranectin levels (median 13.4 vs 13.4 mg/L; p=0.9), and no drifting over years (2001) (2002) (2003) (2004) ) could be detected for controls of 3.6 and 14.4 mg/L, respectively. Furthermore, the measured value of the plasma standard used in the present analyses (11.7 mg/L) was comparable with the previously used standard (11.3 mg/L). Based on the results of these control procedures and the high stability of tetranectin in blood samples (32) , we consider the measured tetranectin values in the present study to be trustworthy.
The overall high levels of tetranectin in the present patient series may be explained by the fact that, in contrast to the above-mentioned ovarian cancer patient series, all patients in this series were pretreated with paclitaxel as part of their first-line chemotherapy. The extratumoral (antiangiogenic) effects of paclitaxel are wellknown (33, 34) . It could be speculated that the previous exposure to paclitaxel caused alterations in the fibrinolytic regulation system. Alternatively, paclitaxel might have interfered with the tetranectin metabolism pathways. However, there was no correlation between tetranectin level and the number of cycles of first-line chemotherapy (r=0.03; p=0.79).
YKL-40 is a heparin-binding glycoprotein expressed by several types of cancer cells and by macrophages in the peritumoral stroma (14) . YKL-40 is a growth factor for connective tissue cells, but the exact function of YKL-40 in cancer growth and metastasis is still unknown (14, 15) . YKL-40 has also been revealed to be a potent migration factor for endothelial cells and it may play a role in angiogenesis (35) . Like tetranectin, YKL-40 might thus exert some of its physiological functions in the vicinity of the tumor.
CASA is an epitope on a polymorphic epithelial mucin glycoprotein (MUC1) expressed by many tumor cells. The role of mucins is not yet fully understood but presumed functions are in membrane protection and cell adhesion (36, 37) . The finding of CASA as a chemoresistance predictor in the present study might be explained by the presumption that ovarian cancer cells overexpressing CASA are more resistant to the effects of inflammatory cells and cytokines in the tumor microenvironment, but this hypothesis should be validated. In comparison, the median level of CASA in the present study (6.8 U/mL) is similar to that found in other series of patients with recurrent ovarian cancer (median 6.5 U/mL) (38) .
The findings of the present study might also add a novel tool to the clinical armamentarium for ovarian cancer patients. Whereas cure is possible in patients with primary ovarian carcinoma, recurrent disease is generally considered incurable (1). Patients with recurrent disease are candidates for second-line cytotoxic treatment; palliation of symptoms and improved survival are the main therapeutic goals (1, 2) . Usually, patients with recurrent disease are offered several cycles of second-line chemotherapy before a clinical response evaluation is carried out, but in this palliative clinical setting the potential benefit of the second-line therapy must be carefully balanced against the potential toxicity of the treatment (39, 40) . Patients with chemoresistant disease should alternatively be considered for supportive care.
It is a clinical challenge to select patients with chemoresistant disease. A usable chemoresistance assay must provide high specificity to avoid selection of patients with non-chemoresistant disease that would potentially benefit from cytotoxic treatment. In this respect a high specificity of the assay should be preferred to a high sensitivity. The present combination of tetranectin and CASA measurement had a specificity of 90% and thus a low probability of false-positive prediction of chemoresistance. However, the sensitivity was only 33% and it should be realized that not every patient with chemoresistant disease is identified by the tetranectin and CASA assays. Noteworthily, the clinical utility of pre-treatment determination of the tumor markers should be validated in a large patient cohort in order to establish the proper cutoffs of the markers to be used in clinical management of patients.
The study has some methodological limitations. To optimize homogeneity in the study group we included only patients with imaging-verified recurrence, which may present a selection bias. The benefit of early relapse chemotherapy based on increasing CA 125 levels alone versus delayed chemotherapy based on the presence of solid ovarian cancer relapse is disputed, and is currently under investigation in a randomized trial (EORTC-55955/MRC-OV05).
In this analysis the response status following 4 cycles of second-line chemotherapy was chosen as landmark. However, since the CA 125 level was determined prior to each cycle of chemotherapy, a landmark after 1, 2, 3, etc. cycles might had been selected. Nevertheless, some patients with measurable disease had CA 125 in the normal range throughout the second-line treatment. These patients were evaluated by an imaging-based technique, which was performed only after every second cycle of second-line chemotherapy. To assure the comparability between patients with and without elevated CA 125 levels, a landmark following an even number of cycles was necessary. According to RECIST, patients with stable disease (measurable disease) must have met the stable disease criteria at least once after the start of the secondline chemotherapy and not less than before 6-8 weeks (27) . In a patient with a stable tumor load following 2 cycles and progression after 4 cycles, it may be disputed whether this patient should be assigned to the "stable disease" category or the "progression" category. Therefore, the landmark following 4 cycles of chemotherapy was chosen.
In conclusion, the serological tumor markers tetranectin, CASA and YKL-40 are novel chemoresistance markers in the second-line treatment of patients with ovarian cancer. Furthermore, the combination of tetranectin and CASA significantly improves the prediction of chemoresistance. A prospective confirmatory trial should evaluate if the tumor markers are better predictors of chemoresistance than conventional clinical indicators such as calculation of the treatment-free interval.
